Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastases.

The most important unmet challenge need in the treatment of these patients is better biomarkers, states Ross. Having biomarkers would allow physicians to know which patients will benefit from immunotherapy regimens.

Additionally, biomarkers will help determine who will develop a resistance to immunotherapy so alternative therapies can be identified for the patient, explains Ross.

Videos

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastasis.

Dr. Ross on Biomarker Research Development in Liver Metastasis

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the future treatment landscape of melanoma.

The landscape of melanoma moving forward is multi-faceted, says Ross, particularly with neoadjuvant therapies.

Dr. Ross Discusses the Future Treatment Landscape of Melanoma

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.

Liver metastasis is a very difficult problem for a variety of reasons, explains Ross. It’s possible that the active immunotherapy agents may not be as effective in the liver.

Of the patients who have metastatic disease, 95% of them will have some component of liver metastasis, states Ross.

View more from the European Post-Chicago Meeting

Merrick I. Ross, MD

Articles

Dr. Ross on Biomarker Research Development in Liver Metastasis

Dr. Ross Discusses the Future Treatment Landscape of Melanoma

Dr. Ross on the Treatment of Liver Metastasis in Melanoma